2015 ACVIM Forum Research Abstract Program

For 36 other healthy facility cats, MAX-ACT was measured on days 1, 4 and 8 (Table 1) . All collections were scored as 1 or 2; all values were within normal ranges. Overall medians, means and variances did not differ between days, although individual values did vary. For visual clotting, 33% of paired observations were identical, 66% differed by ≤ 5 sec and 88% by ≤10 sec. For Actalyke, 48% of paired observations differed ≤ 5 sec and 79% differed by ≤10 sec. Intraclass correlation coefficient was 35%. In this study MAX-ACT was similar to the first report of ACT in cats 1 and repeatability was high within a range AE 10 sec. Visual clotting was as repeatable as Actalyke. Procabarbazine is an alkylating agent used in the treatment of granulomatous meningoencephalitis(GME). Side effects of procarbazine include gastrointestinal and hematological side effects. The purpose of this study was to describe procarbazine associated cytopenias in dogs. Medical records were retrospectively reviewed. Data collected included signalment, dosage and duration of procarbazine therapy, clinicopathological findings, and outcome.